![5a-min](https://www.sancuso.com/wp-content/uploads/elementor/thumbs/5a-min-qjyb8ech6bkd08wr6m6yx0r1l62rimgtli25fxeqnk.jpg)
![4a-min](https://www.sancuso.com/wp-content/uploads/elementor/thumbs/4a-min-qjyb8al4ezf7pt27skkgn1p77mlanu1w8zg7itkbcg.jpg)
![3a-min](https://www.sancuso.com/wp-content/uploads/elementor/thumbs/3a-min-qjyb86trnna2fd7oeixyd2ncu33tt1mywgu9lppw1c.jpg)
![1a-min](https://www.sancuso.com/wp-content/uploads/elementor/thumbs/1a-min-qjyb7zb24yzruhilmfoxt4jo304w3gt47fmdri11f4.jpg)
SANCUSO® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days.
Sancuso is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the transdermal system.
The most common adverse reaction (≥ 3%) is constipation.
You are encouraged to report suspected adverse reactions to Cumberland Pharmaceuticals Inc. at 1-833-Sancuso or FDA at 1-800-FDA-1088 or www.fda.gov/ medwatch.